Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93

Mark Bensink,Christine Edwards,Charles Bowers,Jon Campbell

Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93

2018

Mark Bensink
Christine Edwards
Charles Bowers
Jon Campbell

McBride et al.1 recently published what was referred to as “cost-efficiency analyses”. The analyses completed by the authors compared four alternative granulocyte colony-stimulating factor (G-CSF) ...

Keywords:

Filgrastim
Chemotherapy-Induced Febrile Neutropenia
Biosimilar
Intensive care medicine
Medicine
Filgrastim-sndz
Pegfilgrastim

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations